Guojian Chengnuo Biotechnology

Guojian Chengnuo is a clinical-stage biotechnology company based in Beijing, China, specializing in the development of off-the-shelf cell therapies. The company focuses on induced pluripotent stem cell (iPSC) derived Chimeric Antigen Receptor Natural Killer (CAR-NK) cell therapies for the treatment of solid tumors and hematological malignancies. Its lead candidate, CN001, is an iPSC-derived CAR-NK therapy targeting mesothelin, which has received IND approval for clinical trials in solid tumors. Guojian Chengnuo aims to overcome the limitations of traditional CAR-T therapies by providing standardized, scalable, and cost-effective immunotherapy solutions. The company operates a state-of-the-art GMP manufacturing facility to support its clinical pipeline and future commercialization efforts.